Saturday 17 October 2026
Export ALLO’s income statement to Excel — free account
Allogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023. In the quarter to June 2026, revenue grew 20,990.9%, EPS grew 43.5% and free cash flow grew 17.7%, each against the same quarter a year earlier.
1.31
0.03
−2.24%
Follow ALLO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 145.41 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (21.38) | |
P/B ratio |
— | — | — | 1.57 | |
Price to Tangible BV |
— | — | — | 1.57 | |
EV/Sales |
— | — | — | 74.72 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (3.44) | |
EV/FCF |
— | — | — | (3.43) | |
Quick Ratio |
7.92 | 7.70 | 9.42 | 10.48 | |
Current Ratio |
8.19 | 7.93 | 9.65 | 10.72 | |
Net Debt/EBITDA |
5.90 | 6.23 | 6.05 | 7.30 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF/Net income |
0.72 | 0.71 | 0.30 | 0.75 | |
Capex/Depreciation |
(0.11) | 0.00 | 0.00 | (0.11) | |
Interest Coverage |
(130.53) | (135.48) | (153.64) | (136.79) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 662.09% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 449.12% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 268.10% | |
Graham Net Nets |
— | — | — | 0.33 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (32.21%) | |
Free Cash Flow Yield |
— | — | — | (15.00%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.13) | (0.13) | (0.05) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.13) | (0.05) | (0.10) | |
Cash per Share |
1.14 | 1.13 | 1.11 | 1.01 | |
Shareholders Equity per Share |
1.42 | 1.33 | 1.16 | 1.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.42 | 1.33 | 1.16 | 1.33 | |
Free Cash Flow |
(29.93) | (27.60) | (12.92) | (32.15) | |
Working Capital |
228.89 | 225.24 | 244.96 | 308.27 | |
Capital Expenditures |
(0.24) | 0.00 | (0.01) | (0.15) | |
Net Current Asset Value |
136.28 | 134.39 | 156.21 | 226.08 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.03 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
4.60 | 4.83 | 5.00 | 5.41 | |
Average Assets |
514.45 | 482.31 | 451.97 | 510.34 | |
Average Common Equity |
389.54 | 357.36 | 332.13 | 390.37 |
Columns are period end dates